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ABSTRACT Positron Emission Tomography (PET) with appropriate radiotracers
and quantification methods allows the detection of changes in endogenous neurotrans-
mission by determine the reduction in the binding potential (BP) of receptors before
and after experimental challenges. These have typically employed psychostimulants
and PET with dopamine (DA) receptor radiotracers. However, reductions in BP persist
far beyond the increases in the release of the endogenous neurotransmitter, an effect
ascribed to receptor internalization and recycling, a possible confound in repeated
studies. Here we examined the time-course of changes in BP during a nonpharmaco-
logical challenge, moderate levels of sustained pain, shown to induce robust reductions
in m-opioid and DA D2 BP, as measured with [11C]carfentanil and [11C]raclopride. It
was hypothesized that, contrary to pharmacological probes, the use of a more ‘‘physio-
logical’’ stimulus would not be associated with persistent changes in the BP measures.
The pain challenge was associated with reductions in m-opioid receptor BP in several
cortical and subcortical regions. These did not persist in a subsequent scan. Similar
results were obtained for DA D2 receptor BP, where the pain challenge induced signif-
icant reductions in the caudate nucleus. These data demonstrate that changes in re-
ceptor BP induced by a nonpharmacological challenge did not persist into subsequent
scans. They further suggest differences in the effect of pharmacological and nonphar-
macological probes on PET BP measures. These may reflect varying levels of change
in receptor affinity, receptor internalization, and recycling depending on the type of
challenge employed. Synapse 61:707–714, 2007. VC 2007 Wiley-Liss, Inc.
INTRODUCTION
A significant development in recent functional neu-
roimaging studies has been the ability to characterize
the response of endogenous neurotransmitter systems
to a variety of experimental challenges. Specifically,
external imaging [single-photon emission tomogra-
phy [single photon emission computed tomography
(SPECT)] and positron emission tomography (PET)]
with receptor-specific radiotracers and appropriate
quantification methods have allowed the detection of
changes in the concentration or affinity of receptors
[typically described as the ratio between the two,
Bmax/Kd, also termed binding potential (BP)], provid-
ing an indirect measure of neurotransmitter release.
Such work was pioneered over a decade ago in pri-
mates, where reductions in DA D2 receptor BP were
observed following an amphetamine challenge, and fur-
ther related to the concentration of dopamine (DA) in
extracellular fluid as measured with microdialysis (Innis
et al., 1992). Similar observations were obtained with
other DA-releasing agents (e.g., methylphenidate) and
with a variety of radiopharmaceuticals targeting DA D2
receptors (Dewey et al., 1991; Endres et al., 1997; Lar-
uelle et al., 1995; Narendran et al., 2004; Riccardi et al.,
2006a, 2006b; Volkow et al., 1994).
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However, it has been further observed that the
reduction in DA D2 receptor BP persisted over a pro-
longed period of time (Carson et al., 1997; Laruelle
et al., 1995), which exceeded the increases in DA
release as measured with microdialysis. This has led to
the hypothesis that competition between radiotracer
and receptor protein alone could not explain the
observed results, and that other mechanisms such as
receptor internalization might be responsible (Laruelle,
2000). In addition, recent work has examined the
changes in DA BP during amphetamine administration
using agonist radiotracers that may preferentially bind
to G-protein coupled, high affinity conformational
states of the receptors (Narendran et al., 2004). In
these studies it was observed that the change in the
BP measure was indeed more prominent after the
pharmacological challenge for an agonist tracer, com-
pared with the more traditionally employed antago-
nists. This information then suggests that multiple
processes are reflected by the change in BP after phar-
macological challenges known to release endogenous
neurotransmitters: competition of radiotracer and
endogenous ligand, receptor internalization and recy-
cling, and in the case of agonist radiotracers, possibly
changes in the conformational state of the receptors af-
ter interaction with the endogenous ligand.
These mechanisms still reflect the ‘‘activation’’ of
endogenous neurotransmission, and provide a mea-
sure of this process. However, the persistence of re-
ceptor BP changes over time may represent a con-
founding factor in repeated studies within subjects
and limits the experimental designs that could be
practically utilized in humans.
The present investigation explores whether persistent
changes in the BP measure are also present in studies
employing nonpharmacological challenges. Data from
various laboratories have reported reductions in the BP
measure in response to pain using the m-opioid receptor
agonist radiotracer [11C]carfentanil (Bencherif et al.,
2002; Zubieta et al., 2001), and with the DA D2/D3 re-
ceptor antagonist [11C]raclopride (Scott et al., 2006).
Similar effects have been reported with [11C]raclopride
using a social stress challenge (Pruessner et al., 2004), a
reward task (Zald et al., 2004), and placebo administra-
tion (de la Fuente-Fernandez et al., 2001). Of interest,
and in a number of these studies, the magnitude of the
BP changes observed during these challenges was sub-
stantial. However, and in animal models, the level of DA
release, as measured with microdialysis is typically sub-
stantially greater for pharmacological (e.g., ampheta-
mine administration, from 50 to 400%, depending on the
dose administered) (Heidbreder and Feldon, 1998; Her-
nandez et al., 1987; Hooks et al., 1992), than nonphar-
macological challenges (e.g., sustained pain, 10–50%,
depending on the models) (Marinelli et al., 2005; Rouge-
Pont et al., 1998; Schmidt et al., 2002). These differences
may account for variations in receptor internalization or
affinity induced by the released neurotransmitter,
impacting on the capacity of the receptor sites to recycle
after the challenges.
Here we utilize a challenge, moderate levels of sus-
tained pain, known to activate both dopaminergic and en-
dogenous opioid neurotransmission and to reduce the BP
measure in [11C]raclopride and [11C]carfentanil PET
studies (Zubieta et al., 2001, 2003). Baseline studies pre-
ceded and followed the challenge scan to examine the
persistence of the BP changes. It was hypothesized that,
contrary to studies using psychostimulant challenges,
more ‘‘physiological,’’ nonpharmacological challenges
would not be associated with a prolonged reduction in
the BP measure. This information would be of impor-
tance in PET study design and interpretation, particu-
larly when randomized studies (e.g., challenge, control
condition) are desirable and performed within subjects.
MATERIALS AND METHODS
Subjects
Volunteers were 14 healthy, medication free, right-
handed men 27 6 5 years of age, with an educational
Fig. 1. Carfentanil and Raclopride scan design. Volunteers par-
ticipated in either three 90-min PET scans with [11C]carfentanil (A)
or two 90-min scans with [11C]raclopride (B); each scan consisted of
two 45-min experimental periods. The [11C]carfentanil scans con-
sisted of an initial scan with two baseline conditions (B1 and B2), a
second scan with the pain challenge in the first period followed by a
baseline condition (B4), and a third scan with two additional base-
line conditions (B5 and B6). [11C]raclopride scans consisted of one
scan with a baseline condition (B1) followed by the pain challenge
in the second 45-min period, and a second scan with two additional
baseline conditions (B3 and B4). The timing (in minutes) of post-
challenge baseline conditions is displayed in yellow.
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level 17 6 2 years. Subjects had no personal history
of medical, psychiatric illness, substance abuse or de-
pendence, and no family history of inheritable illnesses.
Volunteers were not taking psychotropic medications or
hormone treatments, were nonsmokers, and did not
exercise in excess of 1 h three times a week. Written
informed consent was obtained in all cases. All the pro-
cedures employed were approved by the University of
Michigan Investigational Review Board for Human
Subject Use and the Radiation Safety Committee.
Fig. 2. Localization and time course of changes in [11C]carfenta-
nil BP following pain administration. After correction for multiple
comparisons, significant pain-induced reductions in m-opioid recep-
tor BP were observed when compared with the first baseline condi-
tion (B1) in the pregenual anterior cingulate cortex and orbitofron-
tal cortex, posterior insula, thalamus, and nucleus accumbens. Z-
scores of statistical significance are represented by the pseudocolor
scale in the center of the image and are superimposed over an ana-
tomically standardized MRI image. The left side of the images corre-
sponds to the left side of the body (ipsilateral to pain; neurological
convention). Plots of l-opioid receptor BP at each time point are pre-
sented above the corresponding brain slice using the mean and
SEM of the data (** P < 0.005; * P < 0.05).
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Study design
Figure 1 shows the overall study design. Radio-
tracer administration for all scans was separated by
30 min to allow for radiotracer decay. Residual radio-
activity between scans represented less than 1.5% of
the peak activity and did not appear to influence
consecutive baseline measures (Figs. 2 and 3). For
[11C]carfentanil scans, 10 subjects participated in
three 90-min scan periods, each of which contained
two conditions. The first scan consisted of two base-
line periods, referred to throughout as B1 and B2.
The 20-min pain stress challenge (see later) was
introduced in the first period of the second scan, 5
min post-tracer administration, and was followed by
another baseline (B4). The third scan, identical to the
first, again consisted of two baseline periods (B5 and
B6). Given the 30-min delay between scans, the onset
times for conditions B4, B5, and B6 thus correspond
to 20, 95, and 140-min postchallenge, respectively.
For [11C]raclopride scans, 4 subjects participated in
two 90-min scan periods. One scan consisted of a
baseline condition (B1) followed by the 20-min pain
stress challenge. The pain challenge was introduced
45 min post-tracer administration. The second scan
included two additional baseline periods (B3 and B4).
Given a 30-min delay between scans, onset times for
conditions B3 and B4 in this experiment were thus 50
and 95 min after completion of the 20-min challenge.
Pain stress model
A steady state of muscle pain was maintained for
20 min by a computer-controlled system through the
infusion of small amounts of medication-grade hyper-
tonic saline (5%) into the left masseter muscle. In
this model of sustained deep somatic pain, the inten-
sity of the painful stimulus is controlled using feed-
back from subjects every 15 s to adjust the rate of
infusion of hypertonic saline, as described in detail
elsewhere (Zubieta et al., 2001, 2003). Briefly, a
standard 150 ml bolus of hypertonic saline is adminis-
tered over 15 s to establish the initial step response
of the system. An electronic version of a 10-cm visual
analog scale (VAS) placed in front of the scanner gan-
try is then used by the subject to rate pain intensity
once every 15 s. This signal is fed back to the com-
puter via an analog-digital board, which then adjusts
the infusion rate so that pain is maintained to
achieve a target VAS intensity rating of 40, within a
range of 30–50, for the duration of the challenge. Sub-
jects are informed that the lower end on the scale
denotes ‘‘no pain,’’ whereas the upper bound repre-
sents the ‘‘most intense pain imaginable.’’ This method
allows for the maintenance of pain over the experi-
mental challenge and for comparability of the stimulus
across subjects. In the baseline condition, the subject
was asked simply to remain still in the PET scanner
for the duration of the scan, and the electronic VAS
scale and infusion system were not present.
The sensory and pain-specific affective qualities of
the painful stimulus were assessed after completion
of the pain challenges with the corresponding sub-
scales of the McGill Pain Questionnaire (MPQ; Mel-
zack and Torgerson, 1971) as well as with 0–100 VAS
scales of pain intensity and unpleasantness.
PET and MRI acquisition
PET scans were acquired with a Siemens (Knox-
ville, TN) HR+ scanner in 3D mode (reconstructed
FWHM resolution 5.5 mm in-plane and 5.0 mm axi-
ally), with septa retracted and scatter correction. Par-
ticipants were positioned in the PET scanner gantry,
and two i.v. (antecubital) lines were placed. A light
forehead restraint was used to eliminate intrascan
head movement. [11C]carfentanil was synthesized at
high specific activity (>2000 Ci/mmol) by the reaction
Fig. 3. Localization and time course of changes in [11C]raclopr-
ide BP following pain administration. After correction for multiple
comparisons, significant reductions in Da D2 receptor BP were
observed when compared with the first baseline condition (B1) in
the dorsal caudate. Z-scores of statistical significance are repre-
sented by the pseudocolor scale in the center of the image and are
superimposed over an anatomically standardized MRI image. The
left side of the image corresponds to the left side of the body (ipsilat-
eral to pain; neurological convention). Plots of DA D2 receptor BP
at each time point are presented above the corresponding brain slice
using the mean and SEM of the data (* P < 0.05).
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of [11C]methyliodide and a nonmethyl precursor as
previously described (Jewett, 2001). [11C]raclopride
was synthesized at high specific activity (>2000 Ci/
mmol) by the reaction of O-desmethyl raclopride with
11C-methyl triflate. Ten to fifteen milliCurie were
administered in each of the scans, with a mass of car-
fentanil injected of 0.048 6 0.037 lg/kg per scan and
a mass of raclopride injected of 0.089 6 0.047 lg/kg
per scan. These ensured that the compounds were
administered in tracer quantities, i.e., subpharmaco-
logical doses occupying less than 1% of the available
receptors. Fifty percent of the radiotracer doses were
administered as a bolus, and the remaining 50% by
continuous infusion for the remainder of the study.
Images were reconstructed using iterative algorithms
(brain mode; Fourier rebinning with ordered subsets-
expectation maximization, four iterations, 16 subsets;
no smoothing) into a 128  128 pixel matrix in a 28.8
cm diameter field of view. Attenuation correction was
performed through a 6-min transmission scan (68 Ge
source) obtained prior to the PET study, also with itera-
tive reconstruction of the blank/transmission data fol-
lowed by segmentation of the attenuation image. Small
head motions during emission scans were corrected by
an automated computer algorithm for each subject
before analysis, and the images coregistered to each
other with the same software (Minoshima et al., 1993).
These procedures have coregistration accuracy within
0.58 and 0.5 mm. Time points were then decay-cor-
rected during reconstruction of the PET data.
Image data were then transformed on a voxel-by-
voxel basis into two sets of parametric maps: (a) a
tracer transport measure (K1 ratio), and (b) a recep-
tor-related measure (distribution volume ratio, DVR).
To avoid the need for arterial blood sampling, these
measures were calculated using a modified Logan
graphical analysis (Logan et al., 1996) using the occi-
pital cortex (an area devoid of m-opioid receptors) as
the reference region for [11C]carfentanil and the cere-
bellum (an area devoid of DA D2 receptors) as the ref-
erence region for [11C]raclopride. With the partial
bolus—continuous infusion radiotracer administration
protocol used, the Logan plot becomes linear by 4–5
min after the start of radiotracer administration,
allowing the calculation of receptor measures early af-
ter tracer administration. The slope of the Logan plot
is equal to the (f2 Bmax/Kd) + 1 for this receptor site
(receptor concentration divided by its affinity for the
radiotracer) and it has been referred to as the DVR;
f2 Bmax/Kd (or DVR  1) is the ‘‘receptor related’’ mea-
sure (also termed BP, BP (Mintun et al., 1984)]. The
term f2 refers to the concentration of free radiotracer
in the extracellular fluid and is considered to repre-
sent a constant and very small value. As changes in
Bmax/Kd will cause a change in the slope of the Logan
plot, we measured DVR during both the early and
late phases of each scan. The slope during the early
phase was estimated from 5 to 40 min postinjection,
while the slope for the second phase was estimated
from 45 to 90 min postinjection.
Anatomical MRI scans were acquired prior to PET
scanning on a 1.5 Tesla scanner (Signa, General Elec-
tric, Milwaukee, WI). Acquisition sequences were
axial SPGR Inverse Recovery-Prepared MR [echo
time (TE) ¼ 5.5 ms, repetition time (TR) ¼ 14 ms,
inversion time (TI) ¼ 300 ms, flip angle ¼ 208, num-
ber of excitations (NEX) ¼ 1, 124 contiguous images,
1.5 mm-thickness], followed by axial T2 and proton
density images (TR ¼ 4000, TE ¼ 20 and 100, respec-
tively, NEX ¼ 1, 62 contiguous images, 3 mm thick).
K1 images were then first coregistered to the MR
images and the transformation matrix applied to the
DVR data, followed by MR, K1, and DVR anatomical
standardization the International Consortium for
Brain Mapping (ICBM) stereotactic atlas orientation.
Statistical parametric maps of differences between
conditions (pain vs. baseline) were generated by ana-
tomically standardizing the T1-SPGR MRI of each
subject to the ICBM stereotactic atlas coordinates,
with subsequent application of this transformation to
the DA D2 and m-opioid receptor binding maps. The
accuracy of coregistration and nonlinear warping
algorithms was confirmed for each subject individu-
ally by comparing the transformed MRI and PET
images to each other and the ICBM atlas template.
Image data analysis
Differences between conditions were mapped into
stereotactic space using z maps of statistical signifi-
cance with SPM99 (Welcome Department of Cognitive
Neurology, University College, London, UK) and Mat-
lab (MathWorks, Natick, MA) software, with a general
linear model and correction for multiple comparisons
(Friston et al., 1995). No global normalization was
applied to the data, and therefore the calculations pre-
sented are based on absolute BP (f2 Bmax/Kd) estimates.
Only regions with specific l-opioid or DA D2 receptor
binding were included in the analyses (voxels with
DVR values > 1.2 times the mean global image value
as calculated with SPM99). To compensate for small re-
sidual anatomic variations across subjects and to
improve signal to noise ratios, a three-dimensional
Gaussian filter (FWHM 6 mm) was applied to each
scan. Contrasts were performed on l-opioid and DA D2
BP images separately to assess main effects of pain.
For l-opioid images, the early baseline 1 from scan 1
was compared with the pain condition of scan 2. For
DA D2 images, the early baseline 1 from scan 1 was
compared against the pain condition of scan 1. For
each contrast, one sample, paired t-statistic values
were calculated for each pixel, using the pooled var-
iance across pixels (Worsley et al., 1992). Significant
differences and correlations were detected using a
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statistical threshold that controls a type-I error rate at
P ¼ 0.05 for multiple comparisons, estimated using the
Euler characteristic and the number of pixels in the
gray matter and image smoothness. Z-scores were also
deemed significant if they reached statistical thresholds
after correction for the size of the cluster under consid-
eration with SPM (Friston et al., 1991). BP values for
time-course graphs (in Figs. 2 and 3) were extracted
from image data by averaging the values of voxels con-
tained in an area where significant differences were
obtained in the voxel-by-voxel analysis, down to a
threshold of P < 0.01.
RESULTS
Psychophysical pain ratings
Across both studies, subjects received an average of
2.1 6 1.4 ml of hypertonic saline. This infusion was
associated with an average online pain report, provided
every 15 s, of 34 6 15 on a 0–100 point VAS rating
scale, where 0 represented ‘‘no pain’’ and 100 repre-
sented ‘‘the most intense pain imaginable.’’ Subjects
also provided overall VAS ratings of pain intensity and
unpleasantness at the conclusion of the challenge,
reporting an average of 35 6 15 for pain intensity and
33 6 18 for pain unpleasantness. Overall pain ratings
were also recorded using the weighted word descriptors
of the MPQ, where subjects reported average MPQ
total scores of 21 6 9, MPQ sensory subscale scores of
13 6 7, and MPQ pain affect subscale scores of 1 6 1.
Reductions in l-opioid receptor BP
following a pain stressor
Compared with the early baseline period prior to
pain (B1), significant pain-induced decreases in m-
opioid receptor BP were observed. After correction for
multiple comparisons, significant effects were observed
in the right ventromedial thalamus (ICBM x y z coordi-
nates in mm, 13, 24, 2; z ¼ 8.8; P < 0.0001), the pre-
genual anterior cingulate cortex (x y z, 10, 43, 0; z ¼
8.6; P < 0.0001), the right orbitofrontal cortex (x y z,
29, 27, 14; z ¼ 7.0; P < 0.0001), the right posterior
insula (x y z, 38, 12, 6; z ¼ 6.7; P < 0.005), and the
right nucleus accumbens (x y z, 12, 12, 4; z ¼ 4.3; P
< 0.005). The average percent reductions in the in vivo
l-opioid receptor BP in these regions ranged from 6%
in the nucleus accumbens to 16% in the insula. As
anticipated, the regional localization and magnitude of
these changes reflects previously published reports
using this pain model (Zubieta et al., 2001).
We then examined the persistence of these changes
in m-opioid receptor BP into the baseline periods follow-
ing the pain challenge (B4, B5, and B6). All the regions
where effects were obtained during the pain challenge
showed similarly reduced mean BP values during B4
(20 min after completion of the pain challenge) (Fig. 2),
though these were not significant for all regions (B1 vs.
B4 comparison). Significant reductions were still
observed in the insula (t ¼ 7.2; P < 0.005) and thala-
mus (t ¼ 2.9, P < 0.05), with trends in the same direc-
tion for the cingulate cortex (t ¼ 2.3, P ¼ 0.07) and
orbitofrontal cortex (t ¼ 2.3, P ¼ 0.07), not reaching
statistical significance. The reductions initially ob-
served in the nucleus accumbens were no longer signif-
icant during this period (t ¼ 1.1, P ¼ 0.18).
Contrary to these data, subsequent baselines, with
acquisitions starting at 95 min (B5) and 140 min (B6)
after completion of the pain challenge, did not demon-
strate reductions in BP when compared with B1. The
localization of reductions in [11C]carfentanil binding, as
well as plots of the change in BP over time are pre-
sented in Figure 2.
Reductions in DA D2 receptor BP
following pain
Compared with the first baseline condition (B1),
significant pain-induced decreases in DA D2 receptor
BP were observed in the left (contralateral to pain)
dorsal caudate (x y z coordinates in mm, 13, 6, 13; z ¼
3.2; P < 0.005), where BP was reduced an average of
12%, consistent with other data sets using this chal-
lenge (Scott et al., 2006). In the design used for this
experiment, no significant reductions in the BP mea-
sure were observed for baselines 3 and 4 (50 and 95
min following the completion of the challenge) (cau-
date BP, B1 vs. B3, t ¼ 0.4; P ¼ 0.8; B1 vs. B4, t ¼
0.4; P ¼ 0.7). These data reflect a return to prechal-
lenge BP values in separate scans immediately follow-
ing the challenge scan (50 min following the induction
of caudate DA activation). The localization of reduc-
tions in [11C]raclopride binding, as well as the change
in BP over time are presented in Figure 3.
DISCUSSION
As previously described using pharmacological
probes, a nonpharmacological challenge (sustained
pain) known to induce the activation of endogenous
opioid (Lapeyre et al., 2001) and DA neurotransmis-
sion (Gear et al., 1999) in animal models, also
reduced m-opioid and DA D2 BP in [11C]carfentanil
and [11C]raclopride PET scans, as shown in larger
samples (Scott et al., 2006; Zubieta et al., 2001). How-
ever, and contrary with data acquired after the
administration of pharmacological agents known to
release DA (typically the psychostimulants ampheta-
mine and methylphenidate), the changes in BP did
not persist in subsequent scans following the pain
stressor. A full return to baseline BP levels is
described 50 and 95 min postchallenge. Some residual
effects, albeit with regional variability, were still
observed for periods that immediately followed (20
min after its completion) the noxious challenge, dur-
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ing the same PET scan. These effects were no longer
observed during subsequent PET studies.
This information is of relevance for the design PET
studies when multiple conditions are examined, and
point to important differences in the behavior of
external imaging measures when ‘‘pharmacological’’
and ‘‘physiological’’ probes are used to stimulate en-
dogenous neurotransmission.
Molecular (neurochemical) PET techniques have been
in use for approximately two decades for the quantifica-
tion of receptor concentrations and enzyme activity. More
recent studies also employ them to explore variations in
stimulated endogenous neurotransmission across individ-
uals and pathological states [e.g., schizophrenia, (Abi-
Dargham et al., 1998; Laruelle et al., 1996); substance
abuse, (Martinez et al., 2005)]. The earliest validations
employed primatemodels to examine the effect of amphet-
amine on endogenous DA neurotransmission with (Innis
et al., 1992), or without simultaneous microdialysis
(Dewey et al., 1991). Differences in the sensitivity of radio-
tracers for the detection of changes in endogenous neuro-
transmission have also been recognized, with initial ex
vivo rodent studies reporting [3H]raclopride to be more
sensitive than [3H]N-methylspiperone to detect changes
in extracellular DA (Young et al., 1991). For radioligands
sensitive to endogenous neurotransmitter release (e.g.,
[11C]raclopride), estimates of DA activation in response to
pharmacological challenges have not only proven to be
generalizable across drugs with similar properties (Dewey
et al., 1993), but also highly reproducible within individu-
als in repeated studies (Mawlawi et al., 2001; Volkow
et al., 1993).
However, several studies produced radiotracer time-
activity curves that did not closely model the rapid, pul-
satile response expected from amphetamine-induced DA
release. In fact, a study using [11C]raclopride observed
that striatal tissue concentrations of the radiotracer did
not return to baseline levels for at least an hour following
amphetamine administration, exceeding the expected
time course of DA activation (Carson et al., 1997). An
even greater persistence in altered DA D2 receptor BP
following amphetamine was observed using SPECT and
[123I]IBZM, in this case extending to as long as two hours
after drug administration (Laruelle et al., 1995). While
such findings were significant in the development of new
kinetic modeling techniques that incorporated microdial-
ysis data into the models (Endres et al., 1997), they were
also theoretically important in broadening the hypothe-
sis about what caused the changes in radiotracer BP.
Competition with the endogenous ligand represented
one source of the observed reduction in receptor BP,
given the dose-response relationships between the drug
and the endogenous ligand (Breier et al., 1997). However,
several other mechanisms have been proposed to account
for reductions in radiotracer BP following a drug chal-
lenge, including receptor internalization or recycling
(Chugani et al., 1988), though this process might be lim-
ited in the case of PET with raclopride (Laruelle, 2000).
In addition, agonist radiotracers, such as [11C]carfentanil
(m-opioid receptor) or [11C]N-propyl-norapomorphine
(DA D2 receptor), appear to be more sensitive to chal-
lenges releasing endogenous ligands than do antagonist
tracers, such as [11C]raclopride (Narendran et al., 2004,
2005). This mechanism appears to arise from the
increased likelihood of an agonist to selectively label
high affinity sites, and the conversion of these sites from
high to low affinity following the release of excess endog-
enous neurotransmitter (Kenakin, 1997; Narendran
et al., 2004; Sastre and Garcia-Sevilla, 1994).
Regardless of whether challenge-induced changes in
the externally quantified BP values for a receptor site
are due to one or multiple processes, interpretation dif-
ficulties do arise in the context of multiple studies
within a particular individual. While within-subject
designs are desirable to reduce the statistical noise due
interindividual variability in the measures, residual
effects may introduce an important confound. Further-
more, residual effects may conceivably vary between
individuals depending on factors such as genetic var-
iants or effects of disease processes. For some experi-
mental designs, it would also be desirable to introduce
control and challenge conditions in a randomized fash-
ion and in close proximity to each other.
In the present report we examined the time-course of
changes in m-opioid and DA D2 receptor BP measures
following a nonpharmacological challenge. In contrast to
the data acquired after the administration of ampheta-
mine with DA D2 radiotracers, we observe that the BP
changes were no longer present in sequential scans.
The information presented therefore supports the
use of appropriate nonpharmacological challenges as
an alternative to the more frequently performed stud-
ies with pharmacological probes. These data, together
with the existing literature, further suggest that dif-
ferences may exist between the biological effects of
pharmacological and nonpharmacological challenges
used to stimulate neurotransmitter release in human
functional neuroimaging experiments.
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